New hope for HER2-Mutated lung cancer: phase 3 trial launches
NCT ID NCT06430437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, SHR-A1811, against standard treatments for people with advanced or metastatic non-small cell lung cancer that has a specific change in the HER2 gene. About 300 participants who have not had prior treatment for advanced disease will be enrolled. The goal is to see if the new drug helps delay cancer growth and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH HER2- MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China